Anti-Tumor Necrosis Factor Therapy in Crohn's Disease: More Information and More Questions About the Long Term

Clinical Gastroenterology and Hepatology

Volumn 8, Issue 7, 2010, Pages 556-558

  Bernstein, Charles N ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; INFLIXIMAB; MESALAZINE; METRONIDAZOLE; NITROIMIDAZOLE; ORNIDAZOLE; PLACEBO; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

COLONOSCOPY; CROHN DISEASE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; HUMAN; LOW DRUG DOSE; RECURRENT DISEASE; REMISSION; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; CHRONIC DISEASE; IMMUNOTHERAPY; PROCEDURES; TIME;

CHRONIC DISEASE; CROHN DISEASE; HUMANS; IMMUNOTHERAPY; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77953686372     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2010.04.014     Document Type: Editorial

References (33)

1. Sorrentino D., Paviotti A., Terrosu G., et al. Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease. Clin Gastroenterol Hepatol 8 (2010) 591-599
2. McLeod R.S., Wolff B.G., Ross S., et al. Recurrence of Crohn's disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial. Dis Col Rectum 52 (2009) 919-927
3. Greenstein A.J., Lachman P., Sachar D.B., et al. Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms. Gut 29 (1988) 588-592
4. Wolff B.G. Factors determining recurrence following surgery for Crohn's disease. World J Surg 22 (1998) 364-369
5. Regueiro M., Schraut W., Baidoo L., et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 136 (2009) 441-450
6. McLeod R.S., Wolff B.G., Steinhart A.H., et al. Risk and significance of endoscopic/radiological evidence of recurrent Crohn's disease. Gastroenterology 113 (1997) 1823-1827
7. Rutgeerts P., Geboes K., Vantrappen G., et al. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis. Gut 25 (1984) 665-672
8. Rutgeerts P., Van Assche G., Vermeire S., et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo controlled trial. Gastroenterology 128 (2005) 856-861
9. D'Haens G.R., Vermeire S., Van Assche G., et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology 135 (2008) 1123-1129
10. Sutherland L.R. Mesalamine for the prevention of post-operative recurrence: is nearly there the same as being there?. Gastroenterology 118 (2000) 264-273
11. Rutgeerts P., Hiele M., Geboes K., et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 108 (1995) 1617-1621
12. Marteau P., Lémann M., Seksik P., et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut 55 (2006) 842-847
13. Van Gossum A., Dewit O., Louis E., et al. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after ileo-caecal resection. Inflamm Bowel Dis 13 (2007) 135-142
14. Chermesh I., Tamir A., Reshef R., et al. Failure of Synbiotic 2000 to prevent postoperative recurrence of Crohn's disease. Dig Dis Sci 52 (2007) 385-389
15. Peyrin-Biroulet L., Deltenre P., Ardizzone S., et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol 104 (2009) 2089-2096
16. Louis E., Vernier-Massouille G., Grimaud J.C., et al. Infliximab discontinuation in Crohn's disease patients in stable remission on combined therapy with immunosuppressors: a prospective ongoing cohort study (abstr). Gut 57 (2008) OP302
17. Baert F., Moortgat L., Van Assche G., et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 138 (2010) 463-468
18. Ilnyckyj A., Shanahan F., Anton P.A., et al. Quantification of the placebo response in ulcerative colitis. Gastroenterology 112 (1997) 1854-1858
19. Su C., Lichtenstein G.R., Krok K., et al. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology 126 (2004) 1257-1269
20. Maser E.A., Villela R., Silverberg M.S., et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 4 (2006) 1248-1254
21. Karmiris K., Paintaud G., Noman M., et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 137 (2009) 1628-1640
22. Lichtenstein G.R., Thomsen O.O., Schreiber S., et al. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol 8 (2010) 600-609
23. Schreiber S., Khaliq-Kareemi M., Lawrence I.C., et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 357 (2007) 239-250
24. Rutgeerts P., Diamond R.H., Bala M., et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 63 (2006) 433-442
25. Colombel J.F., Sandborn W.J., Rutgeerts P., et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol 104 (2009) 1170-1179
26. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 359 (2002) 1541-1549
27. Colombel J.F., Sandborn W.J., Rutgeerts P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132 (2007) 52-65
28. Schnitzler F., Fidder H., Ferrante M., et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 58 (2009) 492-500
29. Kamm M.A., Hanauer S.B., Rutgeerts P., et al. Results from an open-label extension of CHARM: steroid-free remission in patients with Crohn's disease who received adalimumab therapy for at least 3 years (abstr). Gastroenterology 136 (2009) A653
30. Rutgeerts P., Colombel J.F., Sandborn W.J., et al. Maintenance of long-term remission in patients with moderately to severely active Crohn's disease treated for 3 years with adalimumab: results from the open-label ADHERE study (abstr). Gastroenterology 136 (2009) A65
31. Colombel J., Rutgeerts P., Reinisch W., et al. One year data from the SONIC study; a randomized double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy (abstr). Gut 58 Suppl II (2009) A69
32. D'Haens G., Baert F., van Assche G., et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371 (2008) 660-667
33. Nugent Z., Blanchard J.F., and Bernstein C.N. A population based study of health care resource use among infliximab users. Am J Gastroenterol (2010) [Epub ahead of print]